4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Retained Earnings data on file, last reported at -$785.1 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 25.78% year-over-year to -$785.1 million in Q1 2026; TTM through Mar 2026 was -$785.1 million, a 25.78% decrease from a year earlier, with the FY2025 full-year figure at -$716.3 million, down 24.32% from the prior year.
• Retained Earnings for Q1 2026 stood at -$785.1 million, down from -$716.3 million in the prior quarter.
• Over the last five years, Retained Earnings for FDMT reached as high as $534000.0 in Q3 2023 and fell as low as -$785.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$372.4 million across 5 years, with a median of -$372.8 million in 2023.
• Across the five-year window, Retained Earnings soared 100.19% in 2023 and sank 572560.55% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$314.5 million in 2022, then plunged by 32.06% to -$415.3 million in 2023, then sank by 38.73% to -$576.2 million in 2024, then retreated by 24.32% to -$716.3 million in 2025, then slipped by 9.6% to -$785.1 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$785.1 million in Q1 2026, -$716.3 million in Q4 2025, and -$735.7 million in Q3 2025.